The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Open accessAbstract
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia can directly upregulate the expression of various cellular immune checkpoints (such as programmed cell death‐ligand 1, PD‐L1) in the TME.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Cited by
Sorted by citations
Items 701–800 of 1,001
Pokhrel, A., Yadav, R., Manvar, K., Wu, R., Jaswani, V., Wasserman, C., & Wang, J. C. C. (2023) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096231176220 · Cited by 8
Liu, Y., Zhang, Z., Xi, P., Chen, R., Cheng, X., Liu, J. T., Zhu, Q., Nie, Y., Sun, T., Gong, B., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11356-6 · Cited by 7
Immune Features of Tumor Microenvironment: A Genetic Spotlight
Asadi, M., Zarredar, H., Zafari, V., Soleimani, Z., Saeedi, H., Caner, A., & Shanehbandi, D. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01192-7 · Cited by 8
HOZUMI, C., Iizuka, A., Ikeya, T., Miyata, H., Maeda, C., Ashizawa, T., Nagashima, T., Urakami, K., Shimoda, Y., Ohshima, K., et al. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20432 · Cited by 8
Courtet, K., Laizet, Y., Lucchesi, C., Bessede, A., & Italiano, A. (2020) · Biomarker Research · doi:10.1186/s40364-020-00206-3 · Cited by 8
Gao, S., Ruan, H., Liu, J., Liu, Y., Liu, D., Tong, J., Shi, J., Yang, H., Xu, T., & Zhang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.678694 · Cited by 8
DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC
Wei, J., Lu, J. K., Cao, Y., YAO, G., Huang, Y., Zhao, H., Pan, Y., Feng, Z., Chen, Z., Chen, W., et al. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210811115054 · Cited by 8
Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study
Sobottka, B., Nienhold, R., Nowak, M., Hench, J., Haeuptle, P., Frank, A., Sachs, M., Kahraman, A., Moch, H., Koelzer, V. H., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000387 · Cited by 8
Agaimy, A., Hartmann, A., Trpkov, K., & Hes, O. (2021) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2021.09.004 · Cited by 8
Zhang, L., Su, Z., Hong, F., & Wang, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.832803 · Cited by 9
Potential prognosis index for m6A-related mRNA in cholangiocarcinoma
Zhu, H., Zhao, H., Wang, J., Zhao, S., Ma, C., Wang, D., Gao, H., Yang, F., Ni, Q., Li, H., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09665-3 · Cited by 8
Gui, C., Wei, J., Zhang, C., Tang, Y., Shu, G., Wu, R., & Luo, J. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101726 · Cited by 8
Castillo, J. J. S., Llavata, L., Fort‐Culillas, R., Cobo, P. A., Moreno, R., Codony, C., del Muro, X. G., Alemany, R., Piulats, J. M., & Martín-Liberal, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311143 · Cited by 8
State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era
Bakouny, Z., Flippot, R., Braun, D. A., Lalani, A. A., & Choueiri, T. K. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.014 · Cited by 8
Self-citationMultiomics data reveals the influences of myasthenia gravis on thymoma and its precision treatment
Ruan, X., Lu, X., Gao, J., Jiang, L., Zhu, Y., Zhou, Y., Meng, J., Yan, H., Yan, F., & Wang, F. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29928 · Cited by 9
Yoshida, T., Ohe, C., Ikeda, J., Atsumi, N., Saito, R., Taniguchi, H., Ohsugi, H., Sugi, M., Tsuta, K., Matsuda, T., et al. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.232 · Cited by 8
Conway, J. R., Taylor-Weiner, A. N., Braun, D. A., Bakouny, Z., Choueiri, T. K., & Allen, E. M. V. (2020) · medRxiv · doi:10.1101/2020.10.30.20222356 · Cited by 7
Self-citationXia, Z., Liu, H., Fan, S., Tu, H., Jiang, Y., Wang, H., Gu, P., & Liu, X. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020654 · Cited by 7
Masson, C., Thouvenin, J., Boudier, P., Maillet, D., Kuchler‐Bopp, S., Barthélémy, P., & Massfelder, T. (2023) · Cancers · doi:10.3390/cancers15123159 · Cited by 7
Li, W., Huang, Y., Xiao, M., Zhao, J., Du, S., Wang, Z., Hu, S., Yang, L., & Cai, J. (2024) · iScience · doi:10.1016/j.isci.2024.109160 · Cited by 8
Self-citationTang, Y., Chen, J., Zhang, M., Hu, X., Guo, J., Zhang, Y., Chen, Y., Liu, H., Zhao, J., Chen, N., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00756-x · Cited by 7
Raupach, E. A., Hegde, A. M., Garcia‐Mansfield, K., Alcantara, M. B., Rose, D. L., Halperin, R. F., Orlando, K. A., Lang, J. D., Sharma, R., David‐Dirgo, V., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-0044 · Cited by 7
Li, J., Xu, N., Hu, L., Xu, J., Huang, Y., Wang, D., Chen, F., Wang, Y., Jiang, J., Hong, Y., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04071-7 · Cited by 7
Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression
Puviindran, B. J., Wallace, S., Ayasoufi, K., Lerner, E., & Fecci, P. E. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf006 · Cited by 9
Hou, J., Ju, C., Egan, N. A., Wei, Y., Wang, Y., Dang, M., Zhou, T., Shi, L., Zheng, N., Chen, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202507718 · Cited by 7
Song, Y., Huang, J. H., Wang, K., & Li, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.935650 · Cited by 7
Bigelow, E., Saria, S., Piening, B., Curti, B. D., Dowdell, A. K., Weerasinghe, R. K., Bifulco, C. B., Urba, W. J., Finkelstein, N., Fertig, E. J., et al. (2022) · Cancer Informatics · doi:10.1177/11769351221136081 · Cited by 7
Zhang, L., Cao, L., Li, S., Wang, L., Song, Y., Huang, Y., Xu, Z., He, J., Wang, M., & Li, K. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000475 · Cited by 7
SMARCA4 alterations in non-small cell lung cancer: a systematic review and meta-analysis
Wankhede, D., Grover, S., & Hofman, P. M. (2024) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-209394 · Cited by 7
Yang, X., Li, X., Xu, H., Du, S., Wang, C., & He, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34877 · Cited by 7
Actin like 6A is a prognostic biomarker and associated with immune cell infiltration in cancers
He, Y., Li, G., He, Y., Cai, N., Chen, Z., Mei, B., Chen, X., Zhang, B., Jin, G.-N., & Ding, Z. (2024) · Discover Oncology · doi:10.1007/s12672-024-01388-0 · Cited by 7
Hrizat, A. S., Lin, R., Eberle-Singh, J. A., O’Neill, R., Xia, Y., Testa, J. R., Uzzo, R. G., McCue, P. A., Yang, H., & Li, L. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155774 · Cited by 7
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma
Fu, L., Li, S., Mei, J., Li, Z., Yang, X., Zheng, C., Li, N., Lin, Y., Cao, C., Liu, L., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02319-5 · Cited by 9
Potential roles of PBRM1 on immune infiltration in cholangiocarcinoma.
Li, L., Li, Y., Guo, Y., Li, J., & Jin, H. (2020) · PubMed Central · Cited by 7
Current status and future perspectives of immunotherapy against urothelial and kidney cancer
Kobayashi, T., Takeuchi, A., Nishiyama, H., & Eto, M. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab121 · Cited by 7
Chen, Q., Kuai, Y., Wang, S., Zhu, X., Wang, H., Liu, W., Liang Cheng, C., & Yang, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.782515 · Cited by 7
Yu, M., Liu, X., Han, X., Shen, S., Wang, F., Chen, D., Li, G., Wang, Z., Zuo, Z., & Zhao, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818120 · Cited by 7
Chen, Z., Huang, Z., Hui, J., Chen, Z., Zhang, H., Jiang, Y., & Zeng, W. (2022) · Journal of Oncology · doi:10.1155/2022/7495183 · Cited by 7
Netie: inferring the evolution of neoantigen–T cell interactions in tumors
Lu, T., Park, S., Han, Y., Wang, Y., Hubert, S. M., Futreal, P. A., Wistuba, I. I., Heymach, J. V., Reuben, A., Zhang, J. J., et al. (2022) · Nature Methods · doi:10.1038/s41592-022-01644-7 · Cited by 7
Zhang, S., Xia, K., Chang, Y., Wei, Y., Xiong, Y., Tang, F., Peng, J., & Ouyang, Y. (2021) · Vaccines · doi:10.2139/ssrn.3922641 · Cited by 7
Chen, P., Li, Z., Liang, Y., Wei, M., Jiang, H., Chen, S., & Zhao, Z. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s407005 · Cited by 7
Genomic profiles of renal cell carcinoma in a small Chinese cohort
Tai, S., Xu, D., Yu, Z., Guan, Y., Yin, S., Xiao, J., Xue, S., & Liang, C. Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1095775 · Cited by 7
Shi, H., Gao, L., Yin, H. X., & Jiang, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6716 · Cited by 6
Jia, L., Cowell, L. G., & Kapur, P. (2024) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000428 · Cited by 7
Lin, Z., Zhang, Y., & Zhang, L. (2020) · 癌症：英文版 · doi:10.1002/cac2.12070 · Cited by 7
Han, W., Xu, X., Che, K., Ma, G., Li, D., Zhang, M., Jiao, W., & Niu, H. (2020) · Disease Markers · doi:10.1155/2020/8841859 · Cited by 7
Kim, J., Park, J. Y., Shin, S., Lim, B. J., & Go, H. (2021) · Cancers · doi:10.3390/cancers13061199 · Cited by 7
New molecular tumor markers for endometrial cancer.
Numa, F., Umayahara, K., Suehiro, Y., Suminami, Y., Oga, A., Sasaki, K., & Kato, H. (2001) · PubMed · Cited by 7
Is tumor mutational burden predictive of response to immunotherapy?Preprint
Gurjao, C., Tsukrov, D. I., Imakaev, M., Luquette, L. J., & Mirny, L. A. (2023) · doi:10.7554/elife.87465.1 · Cited by 8
Long, W., Li, F., Mao, N., Wu, N., Peng, G., Wang, L., & Ma, X. (2025) · Medicine · doi:10.1097/md.0000000000042785 · Cited by 6
Swinging the SWI/SNF complexes for cancer therapy
Jing, H., Zhang, X., & Meng, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.008 · Cited by 6
Xia, W., Wang, H., Dong, Y., Yang, Z., Zhou, Y., Xia, Z., Li, Q., Ren, L., Zheng, Y., Yan, J., et al. (2026) · Advanced Science · doi:10.1002/advs.202512627 · Cited by 6
Chen, Y., Jin, Y., Chen, Y.-K., Cui, C., Yao, J., Zhang, Y., Li, M. H., Cao, G. F., Yang, S., Fan, Y. H., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.005 · Cited by 7
Self-citationPan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment
Li, J., Lin, P., Wang, H., Tang, Z., Yan, X., Chen, X., Yuan, J., Chen, W., & Hong, L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102751 · Cited by 7
Langbein, L. E., Hajjar, R. E., Kim, W. Y., & Yang, H. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00255.2022 · Cited by 8
Gao, H., Sun, H., He, A., Liu, H., Zhang, Z., Li, D., Mao, W., & Qian, J. (2024) · European journal of medical research · doi:10.1186/s40001-024-01689-8 · Cited by 6
Xu, P., Du, Z., Xie, X., Yang, L., & Zhang, J. (2024) · Oncology Letters · doi:10.3892/ol.2024.14559 · Cited by 6
TCGEx: a powerful visual interface for exploring and analyzing cancer gene expression data
Kus, M. E., Sahin, C., Kılıç, E., Askin, A., Ozgur, M. M., Karahanogullari, G., Aksit, A., O’Connell, R. M., & Ekiz, H. A. (2025) · EMBO Reports · doi:10.1038/s44319-025-00407-7 · Cited by 7
PBRM1 loss promotes tumour response to immunotherapy
Otto, G. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.12 · Cited by 6
Laubli, H. P., Dirnhofer, S., & Zippelius, A. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2435-9 · Cited by 6
Cai, W., Wang, Z., Cai, B., Yuan, Y., Kong, W., Zhang, J., Chen, Y., Liu, Q., Huang, Y., Huang, J., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01564-1 · Cited by 6
Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology
DiNatale, R. G., Hakimi, A. A., & Chan, T. A.-T. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa203 · Cited by 6
LoRusso, P., Sekulic, A., Sosman, J., Liang, W., Carpten, J., Craig, D. W., Solit, D., Bryce, A., Kiefer, J., Aldrich, J., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248097 · Cited by 4
Yan, X., Du, G.-W., Chen, Z., Liu, T.-Z., & Li, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679851 · Cited by 6
Evidence of Omics, Immune Infiltration, and Pharmacogenomics for BATF in a Pan-Cancer Cohort
Jia, C., Ma, Y., Wang, M., Liu, W., Tang, F. R., & Chen, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.844721 · Cited by 6
Zheng, Q., Wang, Y.-F., Zhao, R., Han, P., Zhao, J., Li, L., Zhou, X., Li, P., Mo, Y., Pan, X., et al. (2023) · Genes & Genomics · doi:10.1007/s13258-023-01376-8 · Cited by 6
PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer
Liu, L., Niu, L., Zheng, X., Xiao, F., Sun, H., Deng, W., & Cai, J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231205853 · Cited by 6
Betancor, Y. Z., Ferreiro-Pantín, M., Anido, U., Fuentes-Losada, M., León‐Mateos, L., García-Acuña, S. M., Vaamonde-Rodriguez, V., García-Pinel, B., Cebey-López, V., Villaverde-Viaño, R., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374728 · Cited by 6
Ishihara, H., Nishimura, K., Ikeda, T., Fukuda, H., Yoshida, K., Iizuka, J., Kondo, T., & Takagi, T. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.04.008 · Cited by 6
Identification of prognostic chromatin-remodeling genes in clear cell renal cell carcinoma
Yang, Y., Wang, C., Wei, N., Hong, T., Sun, Z., Xiao, J., Yao, J., Li, Z., & Liu, T. (2020) · Aging · doi:10.18632/aging.104170 · Cited by 6
Ito, S., Asahina, H., Yamaguchi, N., Tomaru, U., Hasegawa, T., Hatanaka, Y., Hatanaka, K. C., Taguchi, H., Harada, T., Ohira, H., et al. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101364 · Cited by 6
Renal cell carcinoma pathology in 2021: ‘new need for renal cancer immune profiling’
Sobottka, B., Lorch, A., Siliņa, K., van den Broek, M. F., & Moch, H. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000864 · Cited by 6
Nong, J., Gu, Y., Yao, S., & Zhang, Y. (2021) · Medicine · doi:10.1097/md.0000000000026650 · Cited by 6
Miao, Q., Zhang, L., Zheng, X., Jiang, K., Wu, B., & Lin, G. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-761 · Cited by 6
Yoshikawa, Y., Yamada, Y., Emi, M., Atanesyan, L., Smout, J., de Groot, K., Savola, S. P., Nakanishi, Y., Kanematsu, A., Nojima, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15170 · Cited by 6
Park, H. J., Qin, L., Bakouny, Z., Krajewski, K. M., Allen, E. M. V., Choueiri, T. K., & Shinagare, A. B. (2022) · The Oncologist · doi:10.1093/oncolo/oyac034 · Cited by 7
Self-citationChen, C., Yang, R., Zhang, J., & Xu, H. (2022) · Cancer Medicine · doi:10.1002/cam4.4733 · Cited by 6
Sun, L., Li, B., Wang, B., Li, J., & Li, J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s352773 · Cited by 6
Xu, Y., Zheng, Q., Zhou, T., Ye, B., Xu, Q., & Meng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887318 · Cited by 7
Chen, Y., Hu, W., Wei, X., Zhang, L., Shao, Y., Tian, J., Wang, D., & Wu, B. (2023) · Translational Andrology and Urology · doi:10.21037/tau-23-65 · Cited by 6
Wynja, E., Solomon, B. M., & Bleeker, J. S. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000238 · Cited by 6
Gondal, M. N., Cieslik, M. P., & Chinnaiyan, A. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.576110 · Cited by 6
Jikuya, R., Fukagawa, A., Ito, D., Ishihara, H., Takemura, K. N., Kashima, S., Kato, T., & Urabe, F. (2025) · International Journal of Urology · doi:10.1111/iju.70091 · Cited by 5
Chen, J., Ran, B., Chen, B., Bai, J., Jian, S., Huang, Y. C., Yang, J., Li, J., Chen, Z., Wei, Q., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112778 · Cited by 5
Meng, Z., Niu, X., Xia, L., Chen, Y., Wang, Z., Wang, H., Ji, P., Cui, W., Wang, Y., & Lü, S. (2023) · Advanced Biology · doi:10.1002/adbi.202200264 · Cited by 5
Personalized treatment using predictive biomarkers in solid organ malignancies: A review
Tang, H., Li, Y. X., Lian, J. J., Ng, H.-Y., & Wang, S. S. Y. (2024) · Tumori Journal · doi:10.1177/03008916241261484 · Cited by 5
PBRM1 loss promotes tumour response to immunotherapy
Otto, G. P. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.7 · Cited by 5
Personalisierte Medizin bei Nierenzelltumoren
Junker, K., & Zeuschner, P. (2019) · Aktuelle Urologie · doi:10.1055/a-0895-9201 · Cited by 5
Li, Y., Ding, Q., Xiong, Z., Wen, H., & Feng, C. (2019) · Aging · doi:10.18632/aging.102392 · Cited by 5
Yuan, B., Li, F., Li, Y., & Chen, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250126 · Cited by 5
Wang, L., Liu, Z., Zhang, W., Zhang, A., & Qu, P. (2021) · BioMed Research International · doi:10.1155/2021/9923434 · Cited by 6
Current and Future Biomarkers in the Management of Renal Cell Carcinoma
Reese, S. W., Calderon, L. P., Khaleel, S. S., & Hakimi, A. A. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.09.003 · Cited by 5
Chen, X., Ding, Q., Lin, T., Sun, Y., Huang, Z., Li, Y., Hong, W., Chen, X., Wang, D., & Qiu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109503 · Cited by 5
Pu, Y., Cai, D., Jin, L., Xu, F., Ye, E., Wu, L., Mo, L., Liu, S., Guo, Q., & Wu, G. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03013-w · Cited by 5
Zhang, L., Chen, Y., Hu, W., Wu, B., Ye, L., Wang, D., & Bai, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1230267 · Cited by 5
Li, Y., Huang, H., Ren, Z., Yuan, Y., Wu, H., & Liu, C. (2023) · BMC Cancer · doi:10.1186/s12885-023-11235-0 · Cited by 5
Zhang, X., Huang, X., Cao, Y., Mao, Y., Zhu, Y., Zhang, Q., Zhang, T., Chang, L., & Wang, C. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154972 · Cited by 5
Current status and future perspective of immunotherapy for renal cell carcinoma
Blas, L., Monji, K., Mutaguchi, J., Kobayashi, S., Goto, S., Matsumoto, T., Shiota, M., Inokuchi, J., & Eto, M. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02446-3 · Cited by 5
Potential protumor function of CD74 in clear cell renal cell carcinoma
Ezaki, A., Yano, H., Pan, C., Fujiwara, Y., Anami, T., Ibe, Y., Motoshima, T., Yatsuda, J., Esumi, S., Miura, Y., et al. (2024) · Human Cell · doi:10.1007/s13577-024-01110-w · Cited by 5
Urlić, I., Šoljić, V., Vukoja, M., Marijanović, I., Kraljević, M., Urlić, M., Marić, S., Vukojević, K., & Filipović, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212120 · Cited by 5
Metadata
- Authors
- Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, M. D., Ho, T., Motzer, R. J., Signoretti, S., Kaelin, W. G., Choueiri, T. K., & Van Allen, E. M.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb, New York, NY 10154, USA.
- Columbia University Irving Medical Center (US)
- Johns Hopkins University (US)
- Mayo Clinic in Arizona (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Choueiri, Toni K.
- ORCID
- Miao, Diana
- Margolis, Claire A.
- Gao, Wenhua
- Voss, Martin H.
- Li, Wei
- Martini, Dylan J.
- Bossé, Dominick
- Wind-Rotolo, Megan
- Tracy, Adam
- Giannakis, Marios
- Hodi, Frank Stephen
- Drake, Charles G.
- Ball, Mark W.
- Allaf, Mohamad E.
- Snyder, Alexandra
- Hellmann, Matthew D.
- Ho, Thai
- Motzer, Robert J.
- Signoretti, Sabina
- Kaelin, William G.
- Choueiri, Toni K.
- Van Allen, Eliezer M.
- Venue
- Science
- Published
- 2018-02-16
- Volume
- 359
- Issue
- 6377
- Pages
- 801-806
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6035749
- OpenAlex
- W2782183686
- Cited by
- 1,249
- References
- 57
- Citations by year
- 2026: 73 · 2025: 93 · 2024: 153 · 2023: 164 · 2022: 186 · 2021: 195 · 2020: 179 · 2019: 113 · 2018: 89
- FWCI
- 54.48
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (K08 CA188615, U24CA224316)
- Howard Hughes Medical Institute (Medical Research Fellowship)
- American Association for Cancer Research (KureIt Grant for Kidney Research)
- NIH Office of the Director (P30 CA008748)
- Bristol-Myers Squibb (II-ON Consortium)
- Dana-Farber Cancer Institute (Loker Pinard Funds for Kidney Cancer Research)
- Dana-Farber/Harvard Cancer Center (Kidney SPORE)
- BroadNext10
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- clear cell renal cell carcinoma, immune checkpoint inhibitors, SWI/SNF complex, PBRM1 mutation, tumor response prediction, antitumor immunity, interferon-gamma, T cell-mediated killing, metastatic renal cell carcinoma, cancer genomics
- MeSH terms
- Carcinoma, Renal Cell, Chromosomal Proteins, Non-Histone, Humans, Immunotherapy, Kidney Neoplasms, Mutation, Transcription Factors, Cohort Studies, Gene Expression Profiling, Genomics, Exome, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
